搜尋
Onconetix Inc
ONCO添加自選
0.374USD
-0.016-4.10%
收盤 05/15, 16:00（美東）報價延遲15分鐘
4.29M總市值
虧損本益比TTM
關於 Onconetix Inc 公司
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Onconetix Inc簡介
公司代碼ONCO
公司名稱Onconetix Inc
上市日期Feb 18, 2022
CEOFedasz (Karina M)
員工數量5
證券類型Ordinary Share
年結日Feb 18
公司地址201 E. Fifth Street
城市CINCINNATI
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編45202
電話15136204101
網址https://www.onconetix.com/
公司代碼ONCO
上市日期Feb 18, 2022
CEOFedasz (Karina M)
Onconetix Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Simon Tarsh
Mr. Simon Tarsh
Independent Director
Independent Director
132.00
-6.06%
Mr. Timothy R. Ramdeen
Mr. Timothy R. Ramdeen
Independent Director
Independent Director
--
--
Dr. Thomas Meier, Ph.D.
Dr. Thomas Meier, Ph.D.
Independent Director
Independent Director
--
--
Ms. Karina M. Fedasz
Ms. Karina M. Fedasz
Interim Chief Executive Officer, Interim Chief Financial Officer
Interim Chief Executive Officer, Interim Chief Financial Officer
--
--
Mr. Andrew J. Oakley
Mr. Andrew J. Oakley
Lead Independent Director
Lead Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Simon Tarsh
Mr. Simon Tarsh
Independent Director
Independent Director
132.00
-6.06%
Mr. Timothy R. Ramdeen
Mr. Timothy R. Ramdeen
Independent Director
Independent Director
--
--
Dr. Thomas Meier, Ph.D.
Dr. Thomas Meier, Ph.D.
Independent Director
Independent Director
--
--
Ms. Karina M. Fedasz
Ms. Karina M. Fedasz
Interim Chief Executive Officer, Interim Chief Financial Officer
Interim Chief Executive Officer, Interim Chief Financial Officer
--
--
Mr. Andrew J. Oakley
Mr. Andrew J. Oakley
Lead Independent Director
Lead Independent Director
--
--
收入明細
單位: USD更新時間: 4月6日 週一
單位: USD更新時間: 4月6日 週一
FY2025
FY2025Q1
FY2024
FY2023
由於公司未披露，未能獲取相關數據
地區USD
名稱
營收
佔比
Switzerland
796.59K
97.70%
United Kingdom
18.78K
2.30%
United States
0.00
0.00%
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 5月14日 週四
更新時間: 5月14日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Altos Venture AG
0.48%
Geode Capital Management, L.L.C.
0.10%
Young (Michael)
0.10%
DRW Securities, LLC
0.07%
HRT Financial LP
0.03%
其他
99.23%
持股股東
持股股東
佔比
Altos Venture AG
0.48%
Geode Capital Management, L.L.C.
0.10%
Young (Michael)
0.10%
DRW Securities, LLC
0.07%
HRT Financial LP
0.03%
其他
99.23%
股東類型
持股股東
佔比
Corporation
8.28%
Investment Advisor
2.28%
Individual Investor
1.86%
Investment Advisor/Hedge Fund
1.69%
Venture Capital
0.31%
Hedge Fund
0.05%
Research Firm
0.02%
其他
85.50%
機構持股
更新時間: 4月1日 週三
更新時間: 4月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2026Q1
29
26.70K
3.85%
+2.19K
2025Q4
31
91.66K
5.89%
+62.90K
2025Q3
31
22.38K
5.65%
+17.05K
2025Q2
47
63.91K
38.67%
+44.58K
2025Q1
54
64.94K
25.23%
+43.00K
2024Q4
54
5.57M
44.93%
+3.81M
2024Q3
55
5.45M
45.59%
+5.19M
2024Q2
54
145.05K
20.85%
-52.13K
2024Q1
56
197.34K
30.36%
-46.00
2023Q4
55
198.08K
30.63%
+320.00
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Altos Venture AG
54.65K
7.89%
+48.30K
+761.52%
Jul 14, 2025
Geode Capital Management, L.L.C.
661.00
0.1%
+661.00
--
Dec 31, 2025
DRW Securities, LLC
7.81K
1.13%
-4.55K
-36.81%
Dec 31, 2025
HRT Financial LP
--
0%
-337.00
-100.00%
Jun 30, 2025
Abante Asesores Gestión, S.G.I.I.C., S.A.
2.94K
0.42%
+2.94K
--
Dec 31, 2025
XTX Markets LLC
2.17K
0.31%
+2.17K
--
Dec 31, 2025
UBS Financial Services, Inc.
1.84K
0.27%
+740.00
+67.21%
Dec 31, 2025
Bruhlmann (Christian)
1.44K
0.21%
--
--
Dec 12, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
Mar 23, 2026
Merger
5→1
Jun 11, 2025
Merger
85→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
公告日期
除權除息日
類型
比率
Mar 23, 2026
Merger
5→1
Jun 11, 2025
Merger
85→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
Sep 11, 2024
Merger
40→1
